145 related articles for article (PubMed ID: 37740779)
1. Reclassification of therapeutic response of unresectable hepatocellular carcinoma to anti-angiogenic therapy and immunotherapy using alpha RECIST.
Xu Y; Yang Y; Ouyang J; Zhou Y; Li L; Ye F; Yang H; Huang Z; Zhou A; Zhang W; Zhou J; Zhao X; Zhao H
Eur Radiol; 2024 Apr; 34(4):2244-2255. PubMed ID: 37740779
[TBL] [Abstract][Full Text] [Related]
2. Comparison of α-Fetoprotein Criteria and Modified Response Evaluation Criteria in Solid Tumors for the Prediction of Overall Survival of Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization.
Zhang YQ; Jiang LJ; Wen J; Liu DM; Huang GH; Wang Y; Fan WZ; Li JP
J Vasc Interv Radiol; 2018 Dec; 29(12):1654-1661. PubMed ID: 30396842
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.
Kawaoka T; Aikata H; Murakami E; Nakahara T; Naeshiro N; Tanaka M; Honda Y; Miyaki D; Nagaoki Y; Takaki S; Hiramatsu A; Waki K; Takahashi S; Chayama K
Oncology; 2012; 83(4):192-200. PubMed ID: 22890083
[TBL] [Abstract][Full Text] [Related]
4. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy.
Bonekamp S; Halappa VG; Geschwind JF; Li Z; Corona-Villalobos CP; Reyes D; Bhagat N; Cosgrove DP; Pawlik TM; Mezey E; Eng J; Kamel IR
Radiology; 2013 Aug; 268(2):431-9. PubMed ID: 23616632
[TBL] [Abstract][Full Text] [Related]
5. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
[TBL] [Abstract][Full Text] [Related]
6. The pattern of tumor progression on first-line immune checkpoint inhibitor-based systemic therapy for Chinese advanced hepatocellular carcinoma -CLEAP 004 study.
Yang CX; Pan YX; Ye F; Zhu XD; Xue J; Li X; Yuan ZG; Zhang L; Xu L; Chen YJ; Wang NY; Sun HC; Liu XF;
Front Immunol; 2024; 15():1310239. PubMed ID: 38711515
[TBL] [Abstract][Full Text] [Related]
7. Early Prediction of the Outcome Using Tumor Markers and mRECIST in Unresectable Hepatocellular Carcinoma Patients Who Underwent Transarterial Chemoembolization.
Ichikawa T; Machida N; Sasaki H; Tenmoku A; Kaneko H; Negishi R; Oi I; Fujino MA
Oncology; 2016; 91(6):317-330. PubMed ID: 27784014
[TBL] [Abstract][Full Text] [Related]
8. Prognostic role of serial alpha-fetoprotein levels in hepatocellular carcinoma treated with locoregional therapy.
Paul SB; Sahu P; Sreenivas V; Nadda N; Gamanagatti SR; Nayak B; Shalimar S; Acharya SK
Scand J Gastroenterol; 2019 Sep; 54(9):1132-1137. PubMed ID: 31483691
[No Abstract] [Full Text] [Related]
9. Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab-bevacizumab.
Campani C; Bamba-Funck J; Campion B; Sidali S; Blaise L; Ganne-Carrié N; Demory A; Sutter O; Larrey E; Evain M; Ghannouchi H; Wagner M; Marra F; Sutton A; Allaire M; Nault JC
Liver Int; 2023 Mar; 43(3):708-717. PubMed ID: 36444741
[TBL] [Abstract][Full Text] [Related]
10. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
Edeline J; Boucher E; Rolland Y; Vauléon E; Pracht M; Perrin C; Le Roux C; Raoul JL
Cancer; 2012 Jan; 118(1):147-56. PubMed ID: 21713764
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.
Personeni N; Bozzarelli S; Pressiani T; Rimassa L; Tronconi MC; Sclafani F; Carnaghi C; Pedicini V; Giordano L; Santoro A
J Hepatol; 2012 Jul; 57(1):101-7. PubMed ID: 22414760
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Outcome of Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma by the Combination of RECIST and Tumor Markers.
Hatooka M; Kawaoka T; Aikata H; Honda F; Nakamura Y; Nakano N; Morio K; Fukuhara T; Kobayashi T; Nagaoki Y; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Awai K; Chayama K
Hiroshima J Med Sci; 2016 Sep; 65(2):25-33. PubMed ID: 29989682
[TBL] [Abstract][Full Text] [Related]
13. Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma.
Shao YY; Liu TH; Hsu C; Lu LC; Shen YC; Lin ZZ; Cheng AL; Hsu CH
Liver Int; 2019 Nov; 39(11):2184-2189. PubMed ID: 31400295
[TBL] [Abstract][Full Text] [Related]
14. Alpha-Fetoprotein, Des-Gamma-Carboxy Prothrombin, and Modified RECIST Response as Predictors of Survival after Transarterial Radioembolization for Hepatocellular Carcinoma.
Lim TS; Rhee H; Kim GM; Kim SU; Kim BK; Park JY; Ahn SH; Han KH; Choi JY; Kim DY
J Vasc Interv Radiol; 2019 Aug; 30(8):1194-1200.e1. PubMed ID: 31235408
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of early response to hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma using the combination of response evaluation criteria in solid tumors and tumor markers.
Miyaki D; Kawaoka T; Aikata H; Kan H; Fujino H; Fukuhara T; Kobayashi T; Naeshiro N; Honda Y; Tsuge M; Hiramatsu A; Imamura M; Hyogo H; Kawakami Y; Yoshimatsu R; Yamagami T; Awai K; Chayama K
J Gastroenterol Hepatol; 2015 Apr; 30(4):726-32. PubMed ID: 25311578
[TBL] [Abstract][Full Text] [Related]
16. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma.
Shao YY; Lin ZZ; Hsu C; Shen YC; Hsu CH; Cheng AL
Cancer; 2010 Oct; 116(19):4590-6. PubMed ID: 20572033
[TBL] [Abstract][Full Text] [Related]
17. mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib.
Meyer T; Palmer DH; Cheng AL; Hocke J; Loembé AB; Yen CJ
Liver Int; 2017 Jul; 37(7):1047-1055. PubMed ID: 28066978
[TBL] [Abstract][Full Text] [Related]
18. Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma.
Raoul JL; Park JW; Kang YK; Finn RS; Kim JS; Yeo W; Polite BN; Chao Y; Walters I; Baudelet C; Lencioni R
Liver Cancer; 2014 Oct; 3(3-4):439-50. PubMed ID: 26280005
[TBL] [Abstract][Full Text] [Related]
19. The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization.
Lee JS; Choi HJ; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Baek SE; Chung YE; Park MS; Kim MJ; Rhee H; Kim SU
Gut Liver; 2020 Nov; 14(6):765-774. PubMed ID: 32050313
[TBL] [Abstract][Full Text] [Related]
20. Potentiality of α-fetoprotein (AFP) and soluble intercellular adhesion molecule-1 (sICAM-1) in prognosis prediction and immunotherapy response for patients with hepatocellular carcinoma.
Cao W; Chen Y; Han W; Yuan J; Xie W; Liu K; Qiu Y; Wang X; Li X
Bioengineered; 2021 Dec; 12(2):9435-9451. PubMed ID: 34696675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]